Cognitive behavioral therapy for insomnia (CBT-I) in patients with fibromyalgia: a systematic review and metaanalysis

Purpose: We aimed to evaluate the effectiveness of CBT-i in patients with fibromyalgia in comparison with other non-pharmacological treatments. Methods: Randomized controlled trials assessing the effects of CBT-i in adults with fibromyalgia, published in English or Spanish, were eligible. Electronic...

ver descrição completa

Detalhes bibliográficos
Autores: Climent Sanz, Carolina, Valenzuela Pascual, Francesc, Martínez-Navarro, Oriol, Blanco Blanco, Joan, Rubí Carnacea, Francesc, García-Martínez, Ester, Soler González, Jorge, Barallat Gimeno, Eva, Gea Sánchez, Montserrat
Tipo de documento: artigo
Estado:Versión aceptada para publicación
Data de publicação:2022
País:España
Recursos:Universitat de Lleida (UdL)
Repositório:Repositori Obert UdL
OAI Identifier:oai:dnet:.___________::8c2c7bb895726bee3b9cf680bae6a38a
Acesso em linha:https://dx.doi.org/10.1080/09638288.2021.1954706
https://hdl.handle.net/10459.1/469859
Access Level:Acceso aberto
Palavra-chave:Fibromyalgia
Insomnia
Sleep
Poor sleep quality
Cognitive behavioral
Therapy for insomnia
Systematic review
Descrição
Resumo:Purpose: We aimed to evaluate the effectiveness of CBT-i in patients with fibromyalgia in comparison with other non-pharmacological treatments. Methods: Randomized controlled trials assessing the effects of CBT-i in adults with fibromyalgia, published in English or Spanish, were eligible. Electronic searches were performed using PubMed, Scopus, The Cochrane Library, WebOfKnowledge and Psicodoc databases in March 2021. The main outcome measures were sleep efficiency and sleep quality. Secondary outcomes included pain, depression, and anxiety. Results: Of 226 studies reviewed, five were included in the meta-analysis. CBT-i compared with non-pharmacological treatments showed no significant improvements in sleep efficiency (p = 0.05; standardized mean difference (SMD) [95% CI] 0.31 [-0.00 to 0.61]). CBT-i showed significant improvements in sleep quality (p = 0.009; SMD [95% CI] - 0.53 [-0.93 to -0.13]), pain (p = 0.002; SMD [95% CI] - 0.41 [-0.67 to -0.16]), anxiety (p = 0.001; SMD [95% CI] - 0.46 [-0.74 to 0.18]) and depression (p = 0.02; SMD [95% CI] - 0.33 [-0.61 to -0.05]), compared to non-pharmacological treatments. Effect sizes ranged from small to moderate. Conclusions: CBT-i was associated with a significant improvement in sleep quality, pain, anxiety, and depression, although these results are retrieved from very few studies with only very low to low quality evidence. Trial registration: The review protocol was registered with PROSPERO (Record ID ¼ CRD42016030161).